Muntner Paul, Whittle Jeff, Lynch Amy I, Colantonio Lisandro D, Simpson Lara M, Einhorn Paula T, Levitan Emily B, Whelton Paul K, Cushman William C, Louis Gail T, Davis Barry R, Oparil Suzanne
Ann Intern Med. 2015 Sep 1;163(5):329-38. doi: 10.7326/M14-2803.
Variability of blood pressure (BP) across outpatient visits is frequently dismissed as random fluctuation around a patient's underlying BP.
To examine the association of visit-to-visit variability (VVV) of systolic BP (SBP) and diastolic BP with cardiovascular disease (CVD) and mortality outcomes.
Prospective cohort study.
Post hoc analysis of ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
25 814 ALLHAT participants.
The VVV of SBP was defined as the SD across SBP measurements obtained at 7 visits conducted from 6 to 28 months after ALLHAT enrollment. Participants without CVD events during the first 28 months of follow-up were followed from the 28-month visit through the end of active ALLHAT follow-up. Outcomes included fatal coronary heart disease (CHD) or nonfatal myocardial infarction, all-cause mortality, stroke, and heart failure.
During follow-up, 1194 fatal CHD or nonfatal MI events, 1948 deaths, 606 strokes, and 921 heart failure events occurred. After multivariable adjustment, including for mean SBP, the hazard ratio comparing participants in the highest versus lowest quintile of SD of SBP (≥14.4 mm Hg vs. <6.5 mm Hg) was 1.30 (95% CI, 1.06 to 1.59) for fatal CHD or nonfatal MI, 1.58 (CI, 1.32 to 1.90) for all-cause mortality, 1.46 (CI, 1.06 to 2.01) for stroke, and 1.25 (CI, 0.97 to 1.61) for heart failure. Higher VVV of diastolic BP was also associated with CVD events and mortality.
Long-term outcomes were not available.
Higher VVV of SBP is associated with an increased risk for CVD and mortality. Future studies should examine whether reducing VVV of BP lowers this risk.
National Institutes of Health.
门诊就诊时血压(BP)的变异性常被视为患者基础血压周围的随机波动而被忽视。
研究收缩压(SBP)和舒张压的就诊间变异性(VVV)与心血管疾病(CVD)及死亡结局之间的关联。
前瞻性队列研究。
ALLHAT(抗高血压和降脂治疗预防心脏病发作试验)的事后分析。
25814名ALLHAT参与者。
SBP的VVV定义为ALLHAT入组后6至28个月内7次就诊时获得的SBP测量值的标准差。在随访的前28个月内无CVD事件的参与者从第28个月就诊开始直至ALLHAT积极随访结束。结局包括致命性冠心病(CHD)或非致命性心肌梗死、全因死亡率、中风和心力衰竭。
随访期间,发生了1194例致命性CHD或非致命性MI事件、1948例死亡、606例中风和921例心力衰竭事件。经过多变量调整,包括平均SBP,比较SBP标准差最高与最低五分位数参与者(≥14.4 mmHg对<6.5 mmHg),致命性CHD或非致命性MI的风险比为1.30(95%CI,1.06至1.59),全因死亡率为1.58(CI,1.32至1.90),中风为1.46(CI,1.06至2.01),心力衰竭为1.25(CI,0.97至1.61)。舒张压较高的VVV也与CVD事件和死亡率相关。
无法获得长期结局。
SBP的较高VVV与CVD和死亡风险增加相关。未来研究应探讨降低血压的VVV是否能降低这种风险。
美国国立卫生研究院。